Systemic Therapies Coming Soon for Atopic Dermatitis, with Jonathan Silverberg, MD, PhD

Published on: 

This interview with Silverberg featured a discussion of new data on systemic therapies for various dermatologic conditions.

In an interview with HCPLive editorial team, Jonathan Silverberg, MD, PhD, MPH, known for his work as director of clinical research at George Washington University’s School of Medicine and Health Sciences, discussed several new systemic therapies for different dermatologic conditions.

This discussion covered the topics featured in Silverberg’s presentation at the Revolutionizing Atopic Dermatitis (RAD) 2024 Annual Meeting in Chicago, Illinois. Silverberg touched on the major points covered in his discussion.

“I had the privilege of covering the systemic therapies that are coming soon,” Silverberg explained. “We have a number of important treatment options that are very much on the horizon. The 2 biggies that are really right within our grasp in the US would be lebrikizumab, which is a biologic that targets interleukin-13…and it is currently approved in Europe. We've had some delays on technical hitch stuff, nothing related to the drug, but we're looking forward to getting that approval within the next few months for moderate to severe atopic dermatitis as a potential first line biologic option to be used.”

Silverberg also noted that in a few months following lebrikizumab, it is expected that a US Food and Drug Administration (FDA) approval in the United States will be occur for nemolizumabthe monoclonal antibody designed to inhibit IL-31. IL-31 is known to play an important role in itch and atopic dermatitis and prurigo nodularis.

“We should have it approved within the next year for both prurigo nodularis and atopic dermatitis,” Silverberg explained. “It's likely we'll get prurigo nodularis first, but we're really excited to get it soon for atopic dermatitis. So this is not just some theoretical thing. We're really close. We've got phase 3 data for both of these drugs that look really good and we've got really clean safety profiles, really good efficacy.”

To learn more about this topic, view the full interview segment posted in this summary above.

The quotes contained in this description were edited for the purposes of clarity.